A5016281859- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- RNA Interference and Gene Delivery
- Macrophage Migration Inhibitory Factor
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Neuroblastoma Research and Treatments
- Cancer therapeutics and mechanisms
- Advanced biosensing and bioanalysis techniques
- Sarcoma Diagnosis and Treatment
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Synthetic Organic Chemistry Methods
Fred Hutch Cancer Center
2020-2023
University of Washington
2022-2023
Abstract Acute myeloid leukemia (AML) patients have a wide array of cytogenetic and molecular aberrations, which can influence response to therapy. Monosomy 7 is rare subset within pediatric AML (prevalence <2%) that highly associated with poor outcomes. Fusions involving the anaplastic tyrosine kinase ( ALK ) gene were exclusively identified in 14.3% this high‐risk cohort, while absent across all other AML. Given dismal outcomes monosomy 7, we evaluated use crizotinib, an FDA‐approved...
Acute Myeloid Leukemia (AML) patients have a wide array of cytogenetic and molecular aberrations which can influence response to therapy. Monosomy7 (Mono7) is rare subset within pediatric AML (prevalence 4-5%), that highly associated with poor outcomes. Fusions involving the ALK gene (14.3%) were exclusively identified this high-risk cohort while absent across all other AML. Given dismal outcomes Mono7, we evaluated use crizotinib, an FDA-approved tyrosine kinase inhibitor, used treat...